Menopause, Salpingectomy, Tubal Ligation
Conditions
Keywords
Salpingectomy, Sterilization, Tubal ligation, Opportunistic salpingectomy, Menopausal age
Brief summary
The aim of this study is to evaluate the long-term safety of on the onset of menopause.
Detailed description
The aim of this study is to evaluate the long-term safety of on the onset of menopause. To investigate the effect of Opportunistic Salpingectomy on the age of menopause, we will compare age of menopause in women who underwent sterilization through opportunistic salpingectomy with a control group consisting of women who underwent sterilization by tubal ligation or who had no sterilization.
Interventions
PROCEDUREOpportunistic salpingectomy / bilateral salpingectomy
An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.
Sponsors
Catharina Ziekenhuis Eindhoven
Radboud University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Intervention group * Undergoing an Opportunistic Salpingectomy as sterilization method * Premenopausal status at enrolment * Age between 30 and 45 years * Will have residual ovarian tissue after surgery * Able to understand the written or spoken Dutch language * Gives consent for participating in surveys Control group * Premenopausal status at enrolment * Either sterilization by tubal ligation or no sterilization at all * Age between 35 and 45 years * Able to understand the written or spoken Dutch language * Gives consent for participating in surveys
Exclusion criteria
* Postmenopausal status at enrolment * Under the age of 35 or above 45 * Previous salpingectomy of oophorectomy * Previous hysterectomy * Women with abnormal karyotype (such as Turner Syndrome and Fragile X syndrome) * Underwent chemotherapy or radiation * Unable to understand the written or spoken Dutch language
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Menopausal age | At end of follow-up (follow up ends at age of menopause with a maximum follow-up time of 15 years) | The age of reaching natural menopause (e.g. last menstruation \> 1 year ago ) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Decision regret | 1 year post surgery and at age of menopause | The decision regret regarding their choice of sterilization method. |
Countries
Netherlands
Outcome results
None listed